Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
YINGST v. NOVARTIS AG et al
Case Number:
2:13-cv-07919
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
November 25, 2014
Novartis' Painkiller Pricing Strategy Deemed Legal
Novartis AG on Monday ducked a putative class action alleging it broke New Jersey consumer fraud laws by charging more for a migraine medicine than for another chemically identical painkiller when a federal judge ruled that, while strategic, the company's pricing scheme wasn't illegal.
-
January 02, 2014
Novartis Jacked Up Painkiller Prices, Class Action Claims
Novartis AG was hit with a proposed consumer class action in New Jersey federal court Tuesday claiming the Swiss pharmaceutical giant sells a popular over-the-counter migraine medication at a higher price than an identical product marketed under a different name.